AveXis (AVXS) PT Lowered to $148.00
AveXis (NASDAQ:AVXS) had its price target decreased by BMO Capital Markets from $150.00 to $148.00 in a report published on Wednesday. BMO Capital Markets currently has an outperform rating on the stock.
AVXS has been the subject of a number of other research reports. Bank of America cut their target price on shares of AveXis from $115.00 to $112.00 and set a buy rating for the company in a research report on Friday, November 10th. Canaccord Genuity set a $110.00 target price on shares of AveXis and gave the stock a hold rating in a research report on Thursday, December 14th. Royal Bank of Canada reaffirmed a hold rating and issued a $92.00 target price on shares of AveXis in a research report on Tuesday, January 9th. Credit Suisse Group reaffirmed an outperform rating and issued a $139.00 target price (up previously from $134.00) on shares of AveXis in a research report on Wednesday. Finally, Chardan Capital reaffirmed a buy rating on shares of AveXis in a research report on Thursday, November 2nd. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and sixteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $123.45.
Shares of AveXis (AVXS) opened at $130.19 on Wednesday. AveXis has a 1 year low of $63.61 and a 1 year high of $132.66. The firm has a market cap of $4,685.06, a P/E ratio of -18.06 and a beta of 2.02.
In other news, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $109.72, for a total transaction of $195,301.60. Following the transaction, the vice president now owns 1,780 shares in the company, valued at approximately $195,301.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Andrew F. Knudten sold 2,000 shares of AveXis stock in a transaction on Monday, December 4th. The shares were sold at an average price of $94.48, for a total transaction of $188,960.00. Following the transaction, the vice president now owns 7,000 shares in the company, valued at approximately $661,360. The disclosure for this sale can be found here. Insiders have sold a total of 40,780 shares of company stock worth $4,570,422 in the last quarter. Corporate insiders own 18.60% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Xact Kapitalforvaltning AB purchased a new position in shares of AveXis during the 4th quarter valued at $316,000. Alkeon Capital Management LLC purchased a new position in shares of AveXis during the 4th quarter valued at $553,000. Element Capital Management LLC purchased a new position in shares of AveXis during the 4th quarter valued at $7,274,000. TIAA CREF Investment Management LLC lifted its stake in shares of AveXis by 10.3% during the 4th quarter. TIAA CREF Investment Management LLC now owns 69,078 shares of the company’s stock valued at $7,645,000 after buying an additional 6,437 shares in the last quarter. Finally, Teachers Advisors LLC lifted its stake in shares of AveXis by 1.5% during the 4th quarter. Teachers Advisors LLC now owns 89,226 shares of the company’s stock valued at $9,875,000 after buying an additional 1,277 shares in the last quarter. Institutional investors own 82.66% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2018/03/03/avexis-avxs-pt-lowered-to-148-00.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.